CoChat

Complete Removal of Extracellular IgG Antibodies in a Randomized Dose-Escalation Phase I Study with the Bacterial Enzyme IdeS – A Novel Therapeutic Opportunity

Open access
Winstedt, Lena, Järnum, Sofia, Nordahl, Emma Andersson, Olsson, Andreas, Runström, Anna, Bockermann, Robert, Karlsson, Christofer, Malmström, Johan, Palmgren, Gabriella Samuelsson, Malmqvist, Ulf, Björck, Lars, Kjellman, Christian · 2015 · PLOS ONE
Cited by 120

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

UNLABELLED: IdeS is a streptococcal protease that cleaves IgG antibodies into F(ab’)2 and Fc fragments with a unique degree of specificity, thereby providing a novel treatment opportunity of IgG-driven autoimmune conditions and antibody mediated transplant rejection. Here we report the results from a first in man, double blinded and randomized study with single ascending doses of IdeS in healthy, male subjects. Twenty healthy subjects were given intravenous single ascending doses of IdeS. With impressive efficacy IdeS cleaved the entire plasma IgG-pool only minutes after dosing. IgG reached nadir 6-24 hours after dosing and then slowly recovered. The half-life of IdeS was 4.9 (±2.8) hours at 0.24 mg/kg with the main fraction eliminated during 24 hours. Already two hours after IdeS-dosing, the phagocytic capacity of IgG/IgG-fragments was reduced to background levels. Importantly, IdeS has the capacity to inactivate Fc-mediated effector function in vivo, was considered safe with no serious adverse events, and without dose limiting toxicity in this study. The complete, rapid, but temporary removal of IgG provides a new potent therapeutic opportunity in IgG-mediated pathogenic conditions. TRIAL REGISTRATION: ClinicalTrials.gov NCT01802697.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0132011

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 27

  1. U von Pawel-Rammingen, 2002, IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G, EMBO J, 21, 1607, 10.1093/emboj/21.7.1607 · DOI · Paper page
  2. JR Carapetis, 2005, The global burden of group A streptococcal diseases, Lancet Infect Dis, 5, 685, 10.1016/S1473-3099(05)70267-X · DOI · Paper page
  3. K Wenig, 2004, Structure of the streptococcal endopeptidase IdeS, a cysteine proteinase with strict specificity for IgG, Proc Natl Acad Sci U S A, 101, 17371, 10.1073/pnas.0407965101 · DOI · Paper page
  4. B Vincents, 2004, Enzymatic characterization of the streptococcal endopeptidase, IdeS, reveals that it is a cysteine protease with strict specificity for IgG cleavage due to exosite binding, Biochemistry, 43, 15540, 10.1021/bi048284d · DOI · Paper page
  5. BP Johansson, 2008, IdeS: a bacterial proteolytic enzyme with therapeutic potential, PLoS One, 3, e1692, 10.1371/journal.pone.0001692 · DOI · Paper page
  6. KS Nandakumar, 2007, Blocking of experimental arthritis by cleavage of IgG antibodies in vivo, Arthritis Rheum, 56, 3253, 10.1002/art.22930 · DOI
  7. MH Ryan, 2008, Proteolysis of purified IgGs by human and bacterial enzymes in vitro and the detection of specific proteolytic fragments of endogenous IgG in rheumatoid synovial fluid, Mol Immunol, 45, 1837, 10.1016/j.molimm.2007.10.043 · DOI
  8. L Tradtrantip, 2013, Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase, Mol Pharmacol, 83, 1268, 10.1124/mol.113.086470 · DOI
  9. R Yang, 2010, Successful treatment of experimental glomerulonephritis with IdeS and EndoS, IgG-degrading streptococcal enzymes, Nephrol Dial Transplant, 25, 2479, 10.1093/ndt/gfq115 · DOI
  10. J Agniswamy, 2004, Insight of host immune evasion mediated by two variants of group a Streptococcus Mac protein, J Biol Chem, 279, 52789, 10.1074/jbc.M410698200 · DOI · Paper page
  11. U von Pawel-Rammingen, 2002, Streptococcus pyogenes and phagocytic killing, Nat Med, 8, 1044, 10.1038/nm1002-1044 · DOI
  12. C Karlsson, 2012, Proteome-wide selected reaction monitoring assays for the human pathogen Streptococcus pyogenes, Nat Commun, 3, 1301, 10.1038/ncomms2297 · DOI · Paper page
  13. J Teleman, 2013, Automated quality control system for LC-SRM setups, J Proteomics, 95, 77, 10.1016/j.jprot.2013.03.029 · DOI
  14. ME Ackerman, 2011, A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples, J Immunol Methods, 366, 8, 10.1016/j.jim.2010.12.016 · DOI · Paper page
  15. R Vindebro, 2013, Rapid IgG heavy chain cleavage by the streptococcal IgG endopeptidase IdeS is mediated by IdeS monomers and is not due to enzyme dimerization, FEBS Lett, 587, 1818, 10.1016/j.febslet.2013.04.039 · DOI
  16. P Åkesson, 2004, Low antibody levels against cell wall-attached proteins of Streptococcus pyogenes predispose for severe invasive disease, J Infect Dis, 189, 797, 10.1086/381982 · doi:10.1086/381982
  17. D Collen, 1997, Recombinant staphylokinase variants with altered immunoreactivity. III: Species variability of antibody binding patterns, Circulation, 95, 455, 10.1161/01.CIR.95.2.455 · doi:10.1161/01.cir.95.2.455
  18. PJ Declerck, 1994, Prevalence and induction of circulating antibodies against recombinant staphylokinase, Thromb Haemost, 71, 129, 10.1055/s-0038-1642396 · doi:10.1055/s-0038-1642396
  19. D Mainet, 1998, Similar, more than 6-months persisted, antibody and neutralizing activity responses in patients with acute myocardial infarction treated with recombinant or natural streptokinase, Fibrinolysis Proteol, 12, 301, 10.1016/S0268-9499(98)80023-4 · doi:10.1016/s0268-9499(98)80023-4
  20. RJ Brezski, 2009, Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge, Proc Natl Acad Sci U S A, 106, 17864, 10.1073/pnas.0904174106 · DOI
  21. MB Buchalter, 1993, Are streptokinase antibodies clinically important?, Br Heart J, 70, 101, 10.1136/hrt.70.2.101 · doi:10.1136/hrt.70.2.101
  22. SP Iyer, 2014, Kidney Transplantation with Early Corticosteroid Withdrawal: Paradoxical Effects at the Central and Peripheral Skeleton, J Am Soc Nephrol
  23. SC Jordan, 2004, Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial, J Am Soc Nephrol, 15, 3256, 10.1097/01.ASN.0000145878.92906.9F · DOI · Paper page
  24. RA Montgomery, 2000, Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients, Transplantation, 70, 887, 10.1097/00007890-200009270-00006 · DOI · Paper page
  25. AA Vo, 2008, Rituximab and intravenous immune globulin for desensitization during renal transplantation, N Engl J Med, 359, 242, 10.1056/NEJMoa0707894 · DOI · Paper page
  26. AA Vo, 2008, Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab, Am J Transplant, 8, 144, 10.1111/j.1600-6143.2007.02017.x · DOI
  27. AO Ojo, 1997, Delayed graft function: risk factors and implications for renal allograft survival, Transplantation, 63, 968, 10.1097/00007890-199704150-00011 · DOI · Paper page

Cited by

See all 120

Metadata

Authors
Winstedt, L., Järnum, S., Nordahl, E. A., Olsson, A., Runström, A., Bockermann, R., Karlsson, C., Malmström, J., Palmgren, G. S., Malmqvist, U., Björck, L., & Kjellman, C.
Venue
PLOS ONE
Published
2015-07-15
Volume
10
Issue
7
Pages
e0132011
ISSN
1932-6203 (ISSN-L)
OpenAlex
W915184378
Cited by
120
References
1
FWCI
7.39
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.